‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Tempus AI bid to derail DNA patent case hits snag

31 August 2026 Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court.

Biotech

China-origin biotech assets and the hidden question of IP ownership

27 August 2026 As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.